Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Merck & Co Inc Stock Research

MRK

107.31USD-0.05(-0.05%)Market Closed
Watchlist

Market Summary

USD107.31-0.05
Market Closed
-0.05%

MRK Alerts

  • 1 major insider sales recently.
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

MRK Stock Price

MRK RSI Chart

MRK Valuation

Market Cap

272.8B

Price/Earnings (Trailing)

17.88

Price/Sales (Trailing)

4.63

EV/EBITDA

14

Price/Free Cashflow

13.8

MRK Price/Sales (Trailing)

MRK Profitability

EBT Margin

26.32%

Return on Equity

27.82%

Return on Assets

12.09%

Free Cashflow Yield

7.24%

MRK Fundamentals

MRK Revenue

Revenue (TTM)

58.3B

Revenue Y/Y

3.03%

Revenue Q/Q

3.78%

MRK Earnings

Earnings (TTM)

3.1B

Earnings Y/Y

-251.5%

Earnings Q/Q

-311.8%

Price Action

52 Week Range

83.38119.65
(Low)(High)

Last 7 days

0.2%

Last 30 days

-2.1%

Last 90 days

-5.6%

Trailing 12 Months

26.5%

MRK Financial Health

Current Ratio

1.44

MRK Investor Care

Dividend Yield

2.64%

Dividend/Share (TTM)

2.8

Diluted EPS (TTM)

1.22

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for MRK

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-14
MIZELL STEVEN
sold
-463,292
109
-4,250
evp, chief hr officer
2023-08-03
Guindo Chirfi
acquired
3,900,440
105
36,901
chief marketing officer
2023-08-03
Guindo Chirfi
sold (taxes)
-1,901,440
105
-17,989
chief marketing officer
2023-08-03
MIZELL STEVEN
sold
-474,701
105
-4,500
evp, chief hr officer
2023-08-02
Romanelli Joseph
sold
-6,334
107
-59.00
president, human health int?l
2023-08-02
Romanelli Joseph
sold
-3,221
107
-30.00
president, human health int?l
2023-05-04
LeCointe-Cephas Lisa
sold (taxes)
-32,983
118
-279
svp chief ethics & com officer
2023-05-04
Oosthuizen Johannes Jacobus
sold (taxes)
-52,844
118
-447
president, u.s. market
2023-05-04
Zachary Jennifer
sold
-2,250,830
117
-19,141
evp, general counsel
2023-05-04
Oosthuizen Johannes Jacobus
acquired
107,226
118
907
president, u.s. market

1–10 of 50

Which funds bought or sold MRK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-19
BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL
reduced
-17.22
-536,100
4,711,370
1.97%
2023-09-18
WASHINGTON CAPITAL MANAGEMENT, INC
unchanged
-
140,022
1,795,240
1.53%
2023-09-18
CAPE ANN SAVINGS BANK
added
13.19
268,635
1,448,610
0.96%
2023-09-14
IMS Capital Management
reduced
-1.45
97,589
1,514,500
0.84%
2023-09-13
CGC Financial Services, LLC
new
-
173,132
173,132
0.11%
2023-09-12
Prosperity Wealth Management, Inc.
new
-
211,048
211,048
0.14%
2023-09-12
Prosperity Financial Group, Inc.
added
2.91
40,392
388,287
0.34%
2023-09-12
Farther Finance Advisors, LLC
added
10.48
101,691
614,461
0.13%
2023-09-12
DCM Advisors, LLC
reduced
-15.68
-88,626
948,889
0.41%
2023-09-11
BLUEFIN CAPITAL MANAGEMENT, LLC
new
-
426,943
426,943
0.08%

1–10 of 48

Latest Funds Activity

Are funds buying MRK calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MRK
No. of Funds

Schedule 13G FIlings of Merck

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
8.96%
227,205,978
SC 13G/A
Feb 03, 2023
blackrock inc.
8.5%
215,011,385
SC 13G/A
Feb 09, 2022
vanguard group inc
8.36%
211,202,531
SC 13G/A
Feb 01, 2022
blackrock inc.
7.8%
198,224,264
SC 13G/A
Feb 10, 2021
vanguard group inc
8.24%
208,410,644
SC 13G/A
Feb 05, 2021
blackrock inc.
7.8%
196,213,804
SC 13G/A
Feb 12, 2020
vanguard group inc
8.26%
210,542,333
SC 13G/A
Feb 05, 2020
blackrock inc.
7.5%
190,783,225
SC 13G/A

Recent SEC filings of Merck

View All Filings
Date Filed Form Type Document
Aug 15, 2023
4
Insider Trading
Aug 14, 2023
144
Notice of Insider Sale Intent
Aug 07, 2023
10-Q
Quarterly Report
Aug 04, 2023
4
Insider Trading
Aug 04, 2023
4
Insider Trading
Aug 03, 2023
4
Insider Trading
Aug 03, 2023
144
Notice of Insider Sale Intent
Aug 01, 2023
8-K
Current Report
Jul 05, 2023
4
Insider Trading
Jul 05, 2023
4
Insider Trading

Peers (Alternatives to Merck)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
512.5B
29.5B
3.56% 89.32%
78.88
17.36
1.53% 14.16%
423.3B
97.8B
-2.65% 0.10%
32.43
4.33
2.29% -28.92%
272.8B
58.3B
-2.13% 26.48%
17.88
4.63
2.00% -81.24%
189.8B
77.9B
-9.16% -24.26%
8.84
2.44
-23.04% -26.74%
150.1B
45.2B
-5.06% -15.06%
23.72
3.25
-4.15% 20.34%
MID-CAP
6.5B
-
1.75% 544.26%
-74.04
4.1K
-86.94% 71.24%
4.5B
4.6B
-11.49% -16.32%
-66.69
0.98
6.60% 42.04%
SMALL-CAP
1.9B
627.1M
-7.75% -1.79%
-1.34
3.1
-0.20% -204.67%
1.5B
634.0M
-11.88% -19.94%
34.62
2.37
0.62% -24.59%
832.3M
244.3M
-4.13% 4.68%
4.22
3.41
-39.50% -4.99%
830.8M
109.5M
21.79% -27.57%
-5.79
7.59
-2.66% -32.13%
480.0M
453.3M
110.37% -71.69%
-0.39
1.06
-16.04% 55.90%
479.1M
31.2M
-7.77% -52.62%
-4.55
15.37
407.54% -26.47%
269.4M
54.6M
-13.04% -44.44%
-2.97
4.93
9.39% -179.16%
-
2.2B
- -
-
-
-22.39% 63.59%

Merck News

Nasdaq
Merck (MRK) Stock Moves -0.05%: What You Should Know.
Nasdaq,
8 hours ago
Nasdaq
Dow Analyst Moves: MRK.
Nasdaq,
13 hours ago
Marketscreener.com

Returns for MRK

Cumulative Returns on MRK

12.2%


10-Year Cumulative Returns

11.9%


7-Year Cumulative Returns

12.7%


5-Year Cumulative Returns

12.4%


3-Year Cumulative Returns

Risks for MRK

What is the probability of a big loss on MRK?

16.5%


Probability that Merck stock will be more than 20% underwater in next one year

0%


Probability that Merck stock will be more than 30% underwater in next one year.

0%


Probability that Merck stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does MRK drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Merck was unfortunately bought at previous high price.

Drawdowns

Financials for Merck

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue0.8%58,31157,86959,28358,97457,16953,97848,70446,13143,90641,85741,51836,48837,95640,36339,12145,97144,36843,07342,29441,72941,260
  S&GA Expenses1.9%10,38810,19810,04210,18510,0019,7709,6349,4239,1478,9518,9558,4298,9589,5859,45510,36910,22310,01910,10210,10110,117
  R&D Expenses69.0%25,77115,24813,54812,84110,88712,41012,24514,96615,87013,63413,39710,0439,89810,0029,7249,5388,4028,4879,7529,85312,198
EBITDA-100.0%-17,06018,24418,66421,15718,24616,28511,7609,66014,49013,27913,00511,94512,41211,716------
EBITDA Margin-100.0%-0.29*0.31*0.32*0.37*0.34*0.33*0.28*0.23*0.28*0.28*0.34*0.31*0.31*0.30*------
Earnings Before Taxes-64.5%5,41115,23316,44416,84018,52315,75313,8797,4254,8655,8895,8637,7837,4247,9427,17111,27711,59510,4228,7017,9755,510
EBT Margin-100.0%-0.26*0.28*0.29*0.32*0.29*0.28*0.25*0.20*0.19*0.18*0.22*0.20*0.20*0.18*------
Net Income-76.1%3,11113,03014,51915,26016,57914,18013,0497,1975,5717,0287,06711,51810,47810,1469,8439,3139,3628,3996,2203,3471,341
Net Income Margin-100.0%-0.23*0.24*0.26*0.29*0.26*0.27*0.17*0.13*0.14*0.15*0.30*0.28*0.25*0.25*------
Free Cashflow-100.0%-15,67319,09519,76018,95516,09213,12212,0339,40911,33710,25311,04113,09412,81113,440------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-3.1%104,469107,796109,160107,081107,095106,668105,69493,49490,68890,84791,58889,80090,61584,91384,39783,33183,96582,35482,63785,13085,040
  Current Assets-10.3%29,97733,40235,72233,56132,11631,18430,26631,05828,66526,90927,76426,57729,34326,17427,48326,14224,29825,35125,87526,83624,064
    Cash Equivalents-41.7%5,6609,70712,69411,1459,7538,6148,16710,0468,6306,8828,1537,40111,1477,4609,9347,8716,6608,0777,9677,8285,312
  Inventory1.1%5,9305,8635,9115,6145,5355,7745,9535,6035,4996,4025,5546,1286,0565,8465,9785,8555,8475,7125,4405,4165,178
  Net PPE2.2%22,23121,75821,42220,42420,05919,74719,27918,56518,06418,29517,00016,91915,78915,26914,29714,28713,86213,50613,29112,75512,626
  Goodwill-0.1%21,19521,20921,20421,16021,21321,25821,26418,86218,87320,21218,88220,24823919,76718,06919,48019,4901,37618,25318,25818,274
  Current Liabilities1.1%23,39423,13124,23922,99823,16822,31623,87223,72821,90626,36127,32720,40522,17823,48322,22020,68420,08518,54322,20618,58618,128
    LT Debt, Non Current21.4%34,07228,07428,74528,48228,68430,58630,69022,90724,03324,00225,36026,32126,15621,63722,73622,67722,77122,72119,80619,93619,959
Shareholder's Equity-17.5%38,69346,90545,99144,45843,31840,95338,25735,86333,38827,03925,40429,27027,74426,30026,00126,92527,73727,67026,88232,65632,766
  Retained Earnings-12.6%54,19862,03961,08159,92858,43756,25253,69651,69148,77748,88847,36251,10749,72448,27246,60245,80445,29544,06542,57942,18941,523
  Additional Paid-In Capital-0.6%44,21944,46744,37944,24344,11544,27544,23844,14944,03939,61339,58839,48939,37339,69739,66039,56139,48438,76838,80839,76239,741
Accumulated Depreciation1.0%18,43218,25617,98517,92117,79818,49818,19218,15518,23618,73218,16218,57218,18217,70617,68617,28117,04916,62316,32416,56816,567
Minority Interest-31.0%49.0071.0067.0066.0075.0070.0073.0069.0094.0094.0087.0084.0010295.0094.0087.00102131181234237
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-3.8%15,07515,67319,09519,76018,95516,64313,12211,4378,2228,1507,6174,4457,0898,2558,88412,23810,80511,10310,92211,3497,385
  Share Based Compensation5.7%598566541515493488479472481470441437412402388392382361348341326
Cashflow From Investing-168.7%-16,512-6,146-4,960-15,261-15,360-16,908-16,421-9,069-10,094-8,251-9,193-5,159-2,882-4,525-2,5293121,7814,8794,3142,0781,089
Cashflow From Financing68.4%-2,552-8,087-9,119-2,358-1,9302,1093,097-738-2,315-3,440-2,832-6,215-5,516-8,737-8,861-12,416-11,169-12,052-13,160-13,379-10,938
  Dividend Payments1.6%7,2357,1207,0126,9056,8076,7106,6106,5096,4056,3096,2156,0785,9275,8185,6955,5675,4585,3015,1725,1785,176
  Buy Backs226.8%487149-18.00601840840822239-1,2812,3313,7364,9714,7809,6639,2549,6159,0914,8604,023

MRK Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)
$ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Sales$ 15,035$ 14,593$ 29,522$ 30,494
Costs, Expenses and Other    
Cost of sales4,0244,2167,9519,596
Selling, general and administrative2,7022,5125,1824,834
Research and development13,3212,79817,5975,374
Restructuring costs151142218194
Other (income) expense, net1724382591,148
Total Costs, Expenses and Other20,37010,10631,20721,146
(Loss) Income Before Taxes(5,335)4,487(1,685)9,348
Income Tax Provision6375381,4621,092
Net (Loss) Income(5,972)3,949(3,147)8,256
Less: Net Income Attributable to Noncontrolling Interests3572
Net (Loss) Income Attributable to Merck & Co., Inc.$ (5,975)$ 3,944$ (3,154)$ 8,254
Basic (Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)$ (2.35)$ 1.56$ (1.24)$ 3.26
(Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)$ (2.35)$ 1.55$ (1.24)$ 3.25

MRK Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current Assets  
Cash and cash equivalents$ 5,660$ 12,694
Short-term investments718498
Accounts receivable (net of allowance for doubtful accounts of $86 in 2023 and $72 in 2022)11,0309,450
Inventories (excludes inventories of $3,220 in 2023 and $2,938 in 2022 classified in Other assets - see Note 7)5,9305,911
Other current assets6,6397,169
Total current assets29,97735,722
Investments1,2141,015
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,432 in 2023 and $17,985 in 202222,23121,422
Goodwill21,19521,204
Other Intangibles, Net19,66520,269
Other Assets10,1879,528
Total Assets104,469109,160
Current Liabilities  
Loans payable and current portion of long-term debt2,8391,946
Trade accounts payable3,4424,264
Accrued and other current liabilities13,74714,159
Income taxes payable1,4891,986
Dividends payable1,8771,884
Total current liabilities23,39424,239
Long-Term Debt34,07228,745
Deferred Income Taxes9961,795
Other Noncurrent Liabilities7,2658,323
Merck & Co., Inc. Stockholders’ Equity  
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2023 and 20221,7881,788
Other paid-in capital44,21944,379
Retained earnings54,19861,081
Accumulated other comprehensive loss(4,900)(4,768)
Stockholders' equity before deduction for treasury stock95,305102,480
Less treasury stock, at cost: 1,037,678,033 shares in 2023 and 1,039,269,638 shares in 202256,61256,489
Total Merck & Co., Inc. stockholders’ equity38,69345,991
Noncontrolling Interests4967
Total equity38,74246,058
Liabilities and Equity$ 104,469$ 109,160

About Merck